Latest Breaking News On - Mirati therapeutic krazati - Page 1 : comparemela.com

BridgeBio spinout launches with $200M for KRAS cancer drugs

BioPharma

United statesSan franciscoBridgebio pharmaBio pharmaNeil kumarEli wallaceAmgen lumakrasFrank mccormick bioUniversity of californiaDive briefBio oncology therapeuticsAsset managementDeerfield managementBridgebio oncology therapeuticsMirati therapeutic krazatiBridgebio oncology therapeutic

Colorectal cancer market across 8MM to reach $21 8 billion in 2031, forecasts GlobalData

Colorectal cancer market across 8MM to reach $21 8 billion in 2031, forecasts GlobalData
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Thomas walesGenentech tecentriqAmgen lumakrasEight market drug forecastMarket analysisOncology analystMirati therapeutic krazati

AstraZeneca pays $24M to join race for next big KRAS opportunity

AstraZeneca pays $24M to join race for next big KRAS opportunity
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Amgen lumakrasWuxi apptecMirati therapeutic krazatiJiangsu hengrui medicineRevolution medicinesLanova medicines

MHRA authorises Mirati Therapeutics Krazati for non-small cell lung cancer

MHRA authorises Mirati Therapeutics Krazati for non-small cell lung cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United kingdomGreat britainAlan sandlerShobhit baijalRegulatory authorityUniversity hospital birminghamMirati therapeutic krazatiMirati therapeuticsKura oncology

Roche s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors

Data suggests divarasib could be more potent than already approved KRAS inhibitors from Amgen and Mirati, but the study’s authors caution against cross-trial comparisons.

Adrian sacherNew england journalMirati therapeutic krazatiOches divarasib scores phasei win in kras mutated solid tumors